{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T08:18:26Z","timestamp":1769329106935,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI 13\/01546"],"award-info":[{"award-number":["PI 13\/01546"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI\/16\/01912"],"award-info":[{"award-number":["PI\/16\/01912"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ISCIII-Subdirecci\u00f3n General de Evaluaci\u00f3n"},{"name":"Fondo Europeo de Desarrollo Regional (FEDER)"},{"name":"CERCA Programme\/Generalitat de Catalunya"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jinf.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T04:01:22Z","timestamp":1500955282000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Use of IFN-\u03b3 and IP-10 detection in the diagnosis of latent tuberculosis infection in patients with inflammatory rheumatic diseases"],"prefix":"10.1016","volume":"75","author":[{"given":"Raquel","family":"Villar-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"M\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Muriel-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Lacoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Prat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Ruhwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2017.07.004_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","author":"Cantini","year":"2017","journal-title":"Semin Arthr Rheum"},{"issue":"15","key":"10.1016\/j.jinf.2017.07.004_bib2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/eci.11.6","article-title":"The risk of tuberculosis in patients treated with TNF antagonists","volume":"7","author":"Salgado","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.jinf.2017.07.004_bib7","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.jinf.2017.07.004_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jinf.2017.07.004_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.140099","article-title":"Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches","volume":"91","author":"Goletti","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jinf.2017.07.004_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"1645","key":"10.1016\/j.jinf.2017.07.004_bib11","article-title":"The ongoing challenge of latent tuberculosis","volume":"369","author":"Esmail","year":"2014","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"4","key":"10.1016\/j.jinf.2017.07.004_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3109\/09546634.2015.1115815","article-title":"Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?","volume":"27","author":"Johnson","year":"2016","journal-title":"J Dermatol Treat"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib13","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","article-title":"The tuberculin skin test","volume":"17","author":"Huebner","year":"1993","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.jinf.2017.07.004_bib14","first-page":"2511","article-title":"Crohn's disease: a review of current treatment with a focus on biologics","volume":"67","author":"Panes","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/ers.09.20","article-title":"IFN-gamma-release assays to diagnose TB infection in the immunocompromised individual","volume":"3","author":"Dominguez","year":"2009","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.crohns.2008.05.007","article-title":"Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents","volume":"2","author":"Dominguez","year":"2008","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","article-title":"Screening for tuberculosis infection prior to initiation of anti-TNF therapy","volume":"8","author":"Lalvani","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00196608","article-title":"Evaluating the non-tuberculous mycobacteria effect in the tuberculosis infection diagnosis","volume":"35","author":"Latorre","year":"2010","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1183\/09031936.00151413","article-title":"Beyond the IFN-gamma horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis","volume":"43","author":"Chegou","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib20","doi-asserted-by":"crossref","first-page":"e39228","DOI":"10.1371\/journal.pone.0039228","article-title":"A simple method to quantitate IP-10 in dried blood and plasma spots","volume":"7","author":"Aabye","year":"2012","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib22","first-page":"861","article-title":"Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in\u00a0vivo","volume":"142","author":"Ohmori","year":"1993","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib23","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.4049\/jimmunol.162.6.3549","article-title":"The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells","volume":"162","author":"Sauty","year":"1999","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jcp.21815","article-title":"Essential involvement of cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes","volume":"220","author":"Qi","year":"2009","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/erm.11.97","article-title":"IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions","volume":"12","author":"Ruhwald","year":"2012","journal-title":"Expert Rev Mol Diagn"},{"issue":"11","key":"10.1016\/j.jinf.2017.07.004_bib26","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.5588\/ijtld.16.0342","article-title":"Blood and urine inducible protein 10 as potential markers of disease activity","volume":"20","author":"Petrone","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jinf.2017.07.004_bib27","doi-asserted-by":"crossref","first-page":"589471","DOI":"10.1155\/2015\/589471","article-title":"Blood or urine IP-10 cannot discriminate between active tuberculosis and respiratory diseases different from tuberculosis in children","volume":"2015","author":"Petrone","year":"2015","journal-title":"BioMed Res Int"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jinf.2014.02.008","article-title":"High urine IP-10 levels associate with chronic HCV infection","volume":"68","author":"Petrone","year":"2014","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib30","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/039463201002300311","article-title":"Identification of IP-10 and IL-5 as proteins differentially expressed in human complicated and uncomplicated carotid atherosclerotic plaques","volume":"23","author":"Profumo","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jinf.2017.07.004_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-0500-2-19","article-title":"IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay","volume":"2","author":"Ruhwald","year":"2009","journal-title":"BMC Res Notes"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/bmm.12.13","article-title":"MIGRAs: are they the new IGRAs? Development of monokine-amplified IFN-gamma release assays","volume":"6","author":"Kasprowicz","year":"2012","journal-title":"Biomark Med"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib34","first-page":"731","article-title":"Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children","volume":"13","author":"Lighter","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib35","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1183\/09031936.00039010","article-title":"Potential of interferon-gamma-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients","volume":"36","author":"Aabye","year":"2010","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jinf.2017.07.004_bib36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/00365548.2011.632644","article-title":"Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study","volume":"44","author":"Alsleben","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2017.07.004_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jinf.2012.03.017","article-title":"IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country","volume":"65","author":"Vanini","year":"2012","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jinf.2014.06.013","article-title":"IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children","volume":"69","author":"Latorre","year":"2014","journal-title":"J Infect"},{"issue":"10","key":"10.1016\/j.jinf.2017.07.004_bib39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1157\/13126836","article-title":"Diagnosis and treatment of tuberculosis","volume":"44","author":"Ruiz-Manzano","year":"2008","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10067-012-1938-z","article-title":"Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment","volume":"31","author":"Minguez","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1183\/09031936.00129412","article-title":"Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper","volume":"42","author":"Aabye","year":"2013","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib42","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/bjd.12176","article-title":"Evaluating the use of the interferon-gamma response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-alpha therapy: a prospective head-to-head cross-sectional study","volume":"168","author":"Martyn-Simmons","year":"2013","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jinf.2017.07.004_bib43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-008-0519-1","article-title":"Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment","volume":"27","author":"Bocchino","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2017.07.004_bib44","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","article-title":"Risk assessment of tuberculosis in immunocompromised patients. A TBNET study","volume":"190","author":"Sester","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jinf.2017.07.004_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jinf.2017.07.004_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10067-014-2817-6","article-title":"Screening of latent tuberculosis infection by interferon-gamma release assays in rheumatic patients: a systemic review and meta-analysis","volume":"35","author":"Ruan","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jinf.2017.07.004_bib47","doi-asserted-by":"crossref","first-page":"e0141033","DOI":"10.1371\/journal.pone.0141033","article-title":"The significance of sensitive interferon gamma release assays for diagnosis of latent tuberculosis infection in patients receiving tumor necrosis factor-alpha antagonist therapy","volume":"10","author":"Jung","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ped.12885","article-title":"Usefulness of two interferon-gamma release assays for rheumatic disease","volume":"58","author":"Nozawa","year":"2016","journal-title":"Pediatr Int"},{"issue":"1","key":"10.1016\/j.jinf.2017.07.004_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1756-185X.12772","article-title":"Evaluation of interferon-gamma release assay (T-SPOT.TB(\u2122) ) for diagnosis of tuberculosis infection in rheumatic disease patients","volume":"19","author":"Jiang","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.jinf.2017.07.004_bib50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI40594","article-title":"Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV","volume":"121","author":"Casrouge","year":"2011","journal-title":"J Clin Investig"},{"issue":"8","key":"10.1016\/j.jinf.2017.07.004_bib51","doi-asserted-by":"crossref","first-page":"e2858","DOI":"10.1371\/journal.pone.0002858","article-title":"Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10","volume":"3","author":"Ruhwald","year":"2008","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tube.2011.01.001","article-title":"A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis","volume":"91","author":"Ruhwald","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib53","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jinf.2014.07.026","article-title":"Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis","volume":"69","author":"Latorre","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.07.004_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tube.2016.04.009","article-title":"Evaluation of IL-2, IL-10, IL-17 and IP-10 as potent discriminative markers for active tuberculosis among pulmonary tuberculosis suspects","volume":"99","author":"You","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"10.1016\/j.jinf.2017.07.004_bib55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1164\/rccm.201501-0059OC","article-title":"Mycobacteria-specific cytokine responses detect tuberculosis infection and distinguish latent from active tuberculosis","volume":"192","author":"Tebruegge","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib56","doi-asserted-by":"crossref","first-page":"303.e1","DOI":"10.1016\/j.eimc.2015.11.022","article-title":"Guidelines for the use of interferon-gamma release assays in the diagnosis of tuberculosis infection","volume":"34","author":"Santin","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"1","key":"10.1016\/j.jinf.2017.07.004_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.201302-0365OC","article-title":"Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States","volume":"189","author":"Dorman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jinf.2017.07.004_bib58","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jinf.2012.10.017","article-title":"Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatment","volume":"66","author":"Bartalesi","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.07.004_bib59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12879-015-1117-3","article-title":"Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population","volume":"15","author":"Lee","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2017.07.004_bib60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciu796","article-title":"Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study","volume":"60","author":"Munoz","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib61","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/bjd.12544","article-title":"Interferon-gamma release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in\u00a0vivo and in\u00a0vitro analysis","volume":"169","author":"Sauzullo","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jinf.2017.07.004_bib62","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jinf.2016.09.008","article-title":"First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB plus","volume":"73","author":"Petruccioli","year":"2016","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.jinf.2017.07.004_bib63","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1183\/13993003.00510-2016","article-title":"First evaluation of QuantiFERON-TB Gold Plus performance in contact screening","volume":"48","author":"Barcellini","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317302487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317302487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:24:43Z","timestamp":1759008283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445317302487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0163445317302487"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2017.07.004","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of IFN-\u03b3 and IP-10 detection in the diagnosis of latent tuberculosis infection in patients with inflammatory rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}